Drug Controller General Of India (DCGI) has granted restricted emergency use approval to Zydus Cadila’s ‘Virafin’ for treating the patients showing moderate COVID-19 symptoms. Phase III clinical trial studies reported that a larger proportion of patients when administered subcutaneously with Virafin turned out to be RT-PCR negative by day 7, apart from faster recovery as compared to other anti-viral agents.
Zydus Cadila also known Cadila Healthcare Limited is an Indian multinational pharmaceutical company headquartered in Ahmedabad, Gujarat, India primarily engaged in the manufacture of generic drugs.
